CENTOGENE Releases a New Swab Product to Facilitate the Simple Diagnosis of COVID-19

Cambridge, MA, USA & Rostock/Berlin, Germany, April 21, 2020 (Globe Newswire) – CENTOGENE (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, today announced the production and global distribution of CentoSwab™. This sample collection kit is fully validated for pharyngeal sampling in the detection of SARS-CoV-2, which causes COVID-19. Manufactured in Germany, the kit consists of a ethylene oxide-treated package containing a swab and collection tube. This solution is part of the Company’s global initiative to support the logistics and fast diagnosis of COVID-19 as early as possible.

Prof. Arndt Rolfs, CEO of the Company, stated, "We are all interested in stopping the COVID-19 outbreak. The critical solution to handling the pandemic is the early and fast identification of SARS-CoV-2 infected individuals. This should not just be happening at the end of the virus's cycle, after an individual has started demonstrating symptoms and already spread the virus." He continues, "Fighting this pandemic and a further outbreak requires early preventive testing, and in turn, specific medical products which are currently in limited supply. The production and rapid delivery of these materials in large quantities will contribute to a significant decrease in outbreak - as well as a return to normalcy."

Media Contact:

Ben Legg
Corporate Communications

FTI Consulting
Bridie Lawlor